Last reviewed · How we verify
Rivaroxaban + Aspirin
Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation, while aspirin inhibits platelet aggregation.
Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation, while aspirin inhibits platelet aggregation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Rivaroxaban + Aspirin |
|---|---|
| Also known as | Xarelto |
| Sponsor | University of Florida |
| Drug class | Factor Xa inhibitor and antiplatelet |
| Target | Factor Xa and COX-1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Rivaroxaban works by directly inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. Aspirin, on the other hand, inhibits platelet aggregation by irreversibly inhibiting the enzyme cyclooxygenase-1 (COX-1), which is necessary for the production of thromboxane A2, a potent platelet activator.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis and pulmonary embolism
Common side effects
- Gastrointestinal bleeding
- Hemorrhage
- Thrombocytopenia
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |